Professional and Patient Expert recruitment:
Professional Expert questionnaire: PEQ for HTG10153 Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
People and Communities Partners (Patient Expert) form: Expression of interest form for HTG10153 Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
Deadline for responses: midnight on 16 March 2026
- Status:
- In progress
- Technology type:
- Diagnostic
- Decision:
- Selected
- Prioritisation programme:
- HealthTech
- Rationale:
- Topic description to be added shortly.
- Process:
- HTE
- Description:
- Multiple myeloma is a progressive blood cancer that is characterised by uncontrolled proliferation of abnormal plasma cells in a person’s bone marrow, and abnormal antibodies (monoclonal immunoglobulins) in a person’s blood. It affects multiple organs and systems, including the bones, kidneys, blood and immune system. Multiple myeloma is the third most common blood cancer in the UK with over 6,200 new cases reported each year. It is usually incurable, but it can often be managed for several years with different treatment options. After diagnosis, prognostic tests are done to identify people with high-risk disease. High-risk disease may not respond as well to treatment and is more likely to relapse quickly. Current prognostic testing to identify high-risk disease includes using the International Staging System alongside fluorescence in-situ hybridisation on bone marrow plasma cells to identify key genetic abnormalities. Other prognostic tests include immunophenotyping of bone marrow, immunohistochemistry of the trephine biopsy and serum free light chain assays. Gene expression profiling tests identifying activity levels for specific genes may allow healthcare professionals to more accurately estimate the risk of people’s multiple myeloma. Improved categorisation may guide treatment decisions, improve people's knowledge and understanding of the prognosis of their cancer and potentially lead to improved outcomes.
Provisional Schedule
- Professional and Patient Expert recruitment closes:
- 16 March 2026
- Scoping workshop:
- 20 April 2026
- Scope published:
- 05 May 2026
Project Team
- Project lead
- Deonee Stanislaus
Email enquiries
If you have any queries please email HealthTech2@nice.org.uk
Stakeholders
- External assessment group
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust (NuTH)
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2026 | In progress. Scoping has started for this topic. |
| 16 February 2026 | Stakeholder registration opens |
| 16 February 2026 | Professional and Patient Expert recruitment starts |
| 15 December 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our HealthTech programme manual.